Guía de recomendaciones para el tratamiento de la migraña en la práctica clínica

Jm, Láinez; Castillo, José; Vm, González; Otero, M; Mateos,; Leira, Rogelio; Pascual, Julio

doi:10.1157/13101849

Cited by 12 publications

(2 citation statements)

References 8 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Una de las conclusiones obvias de este estudio es que la relación primaria-especializada en este punto en particular ha de mejorarse. Aparte de los aspectos organizativos locales, las recomendaciones diagnósticas y terapéuticas han de ser consensuadas y válidas en el futuro para los dos estamentos [20].…”

Section: Actitud Del Neurólogo Con La Migrañaunclassified

Actitud del neurólogo español frente a la migraña: resultados del proyecto CIEN-mig (I)

Gómez

Río²,

Jiménez³

et al. 2010

RevNeurol

View full text Add to dashboard Cite

show abstract

Section: Actitud Del Neurólogo Con La Migrañaunclassified

Actitud del neurólogo español frente a la migraña: resultados del proyecto CIEN-mig (I)

Gómez

Río²,

Jiménez³

et al. 2010

RevNeurol

View full text Add to dashboard Cite

show abstract

“…Others concern migraine alongside tension and cluster headache (Denmark [12], Italy [13]). Still others specifically target migraine management (Spain [14] and France [15]).…”

Section: Introductionmentioning

confidence: 99%

Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries

2013

View full text Add to dashboard Cite

IntroductionTriptans have been safely and effectively used in the management of migraine for more than fifteen years, and it seems reasonable to wonder what would be the economic impact of moving a specific triptan to OTC availability. The objective of this study was then to examine the economic impact of payer policies of a triptan Rx-to-OTC switch in six EU countries (France, UK, Spain, Italy, Germany and Poland).MethodsA decision model was used to model the budgetary impact of a triptan Rx-to-OTC switch from the third-party payer (TPP) and the societal perspectives, using a one-year timeframe.ResultsFrom the TPP perspective, it is estimated that the current overall direct spending on the management of migraine attacks across the 6 EU Member States is €582 million annually, and that the savings would reach €75 million (13% of the overall direct economic burden of migraine). From the societal perspective, €86 million annually would be added.ConclusionsGiven evidence of effectiveness and safety, and given the potential savings, a triptan Rx-to-OTC switch is a reasonable public policy decision.

show abstract

A review of current European treatment guidelines for migraine

et al. 2009

View full text Add to dashboard Cite

Migraine is one of the ten most disabling disorders worldwide, and despite recent developments in the management of migraine, it remains underdiagnosed and undertreated. Guidelines for the management of migraine aim to improve the quality of patient care and to assist professionals in decision making in relation to the overall healthcare process. Most European countries have published national clinical practice guidelines for migraine treatment. These guidelines need to be kept up-to-date with the most recent best clinical evidence and therapeutic strategies to ensure their optimal use to improve health outcomes. The aim of this review is to compare the English language guidelines available across Europe, analyzing differences and similarities, in order to provide a general overview to assist in assessing whether a European consensus on migraine treatment can be achieved.

show abstract

Guía de recomendaciones para el tratamiento de la migraña en la práctica clínica

Cited by 12 publications

References 8 publications

Actitud del neurólogo español frente a la migraña: resultados del proyecto CIEN-mig (I)

Actitud del neurólogo español frente a la migraña: resultados del proyecto CIEN-mig (I)

Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries

A review of current European treatment guidelines for migraine

Contact Info

Product

Resources

About